One platform connecting startups, corporations, research institutions, regions and investors
Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
EDTECH: LEVERAGING AI-POWERED TECHNOLOGIES TO TRANSFORM THE LEARNING EXPERIENCE
1. Technology overview
Galux is a Seoul-based company developing AI for protein design, with its headquarters in Gwanak-gu and an R&D center in Gangseo-gu, Seoul. Chaok Seok is Co-CEO, and Taeyong Park was appointed Co-CEO in July 2026. The company works with pharmaceutical partners to design protein therapeutics.
Its GaluxDesign platform designs proteins from first principles, which the site describes as modality-agnostic, and highlights de novo antibody design with a bioRxiv preprint on efficiency. Partnerships are offered through a Partner with us channel, and the latest disclosed collaboration is with Dong-A ST on antibodies for ADC therapeutics.
2. Highlighted features & specifications
- GaluxDesign platform: proprietary AI that designs proteins from first principles.
- De novo antibody design: AI-designed antibodies supported by a bioRxiv preprint.
- Modality-agnostic approach: the design method is described as applicable across protein modalities.
- Partnership channel: pharma and biotech companies can apply through Partner with us.
- In-house R&D center: a dedicated R&D facility in Seoul supports design and validation.
3. Potential application
Co-development of antibody candidates between a Vietnamese biotech and a design partner. Design of binders for diagnostic reagents. Academic and pharma R&D programs exploring ADC antibodies.
4. Benefits
Designs binders and antibodies computationally from first principles, reducing reliance on screening libraries. The approach is described as modality-agnostic across protein formats. Collaboration with pharma partners gives access to design capability without building an in-house AI team. Public recognition includes the Forbes Asia 100 to Watch 2026 list.
5. Market trends & opportunities
Pharma companies are partnering with AI protein design groups to speed up antibody and biologic discovery. Asian pharma and biotech groups are active in these deals. Vietnamese biotech and pharma firms are early in biologics and may engage through research collaboration or licensing.
6. Other information
Galux, Seoul, Republic of Korea. Named to Forbes Asia 100 to Watch 2026 (August 2026). Taeyong Park appointed Co-CEO alongside Chaok Seok (July 2026). Collaboration with Dong-A ST announced October 2026.
